Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal

SMMT divests its investigational antibiotic ridinilazole to Biossil for upfront cash plus milestone payments and royalties, while shifting focus toward oncology. The asset transfer suggests a portfolio refocus and potential monetization of non-core pipeline exposure rather than a hit to core oncology efforts.

Analysis

SMMT divests its investigational antibiotic ridinilazole to Biossil for upfront cash plus milestone payments and royalties, while shifting focus toward oncology. The asset transfer suggests a portfolio refocus and potential monetization of non-core pipeline exposure rather than a hit to core oncology efforts.